Aurobindo Pharma’s wholly owned subsidiary-- Aurobindo Pharma USA Inc., has entered into a Collaboration and License Agreement on November 22, 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.
Both the parties will co-exclusively commercialize the product. The products, once commercialized, will be manufactured at Partner’s facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date. A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of $90 million for Aurobindo over the development period.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1801.85 |
| Dr. Reddys Lab | 1274.00 |
| Cipla | 1373.15 |
| Zydus Lifesciences | 1078.00 |
| Lupin | 2264.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: